Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.71 |
| ▸ | CA2 | P00918 | 8/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416945 | 0.81 | CA1 (0.49) | CA1CA2CA12ACHECA9 | |
| SCHEMBL4131132 | 0.79 | CA1 (0.65) | CA1CA2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL15600629 | 0.78 | CA1 (0.73) | CA1CA2PTGS2PTGS1CA12 | |
| SCHEMBL12416948 | 0.78 | MAPT (0.53) | CA1CA2PTGS2PTGS1SIRT1 | |
| SCHEMBL12416956 | 0.77 | MAPT (0.48) | CA1CA2CA12ACHECA9 | |
| SCHEMBL15600606 | 0.77 | MAOB (0.63) | CA1CA2CA12ACHECA9 | |
| SCHEMBL12767375 | 0.76 | S100B (0.50) | CA1CA2CA12ACHECA9 | |
| SCHEMBL11438344 | 0.75 | CA2 (0.76) | CA1CA2PTGS2PTGS1CA12 | |
| SCHEMBL11438347 | 0.75 | CA2 (0.76) | CA1CA2PTGS2PTGS1CA12 | |
| SCHEMBL13038181 | 0.75 | CA2 (0.76) | CA1CA2PTGS2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | CA1 1082/4885CA2 2958/4885PTGS2 1147/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | CA1 1082/4885CA2 2958/4885PTGS2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.